litlas
Log inCreate account

Markus Warmuth

Active 1996–2025

39
Papers
18,083
Citations
36
h-index
37
i10-index

Citations

Citations per year for Markus Warmuth1948: 1 citations1988: 1 citations1991: 1 citations1997: 1 citations1998: 2 citations1999: 2 citations2000: 6 citations2001: 1 citations2002: 14 citations2003: 17 citations2004: 24 citations2005: 25 citations2006: 35 citations2007: 44 citations2008: 70 citations2009: 63 citations2010: 95 citations2011: 107 citations2012: 160 citations2013: 223 citations2014: 259 citations2015: 305 citations2016: 324 citations2017: 303 citations2018: 358 citations2019: 900 citations2020: 913 citations2021: 898 citations2022: 667 citations2023: 477 citations2024: 699 citations2025: 331 citations2026: 35 citations1949–1987: no citations, so these years are not shown1989–1990: no citations, so these years are not shown1992–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,529 citing papers, 32.7% of this breakdownChina: 1,426 citing papers, 13.2% of this breakdownGermany: 625 citing papers, 5.8% of this breakdownUnited Kingdom: 622 citing papers, 5.8% of this breakdownItaly: 402 citing papers, 3.7% of this breakdownCanada: 343 citing papers, 3.2% of this breakdownFrance: 331 citing papers, 3.1% of this breakdownSwitzerland: 315 citing papers, 2.9% of this breakdownJapan: 309 citing papers, 2.8% of this breakdownSpain: 240 citing papers, 2.2% of this breakdownAustralia: 224 citing papers, 2.1% of this breakdownNetherlands: 215 citing papers, 2% of this breakdown
0%32.7%Other 20.5%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology51.8%
  • Medicine32.4%
  • Computer Science9.4%
  • Immunology and Microbiology1.8%
  • Chemistry1.2%
  • Neuroscience0.7%
  • Other2.7%

Topics

  • Computational Drug Discovery Methods4.4%
  • Bioinformatics and Genomic Networks3.3%
  • Cancer Genomics and Diagnostics3.2%
  • RNA modifications and cancer3%
  • Epigenetics and DNA Methylation2.7%
  • RNA Research and Splicing2.3%
  • Other81.1%

Coauthors

All papers

Open in search
  1. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

    Authors: Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway - Nature 2012 cited by 8,599

  2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

    Authors: Ying-Nan P. Chen, Matthew J. LaMarche, Ho Man Chan, Peter Fekkes, Jorge García‐Fortanet, Michael Acker, Brandon Antonakos, Christine Hiu-Tung Chen, Zhouliang Chen, Vesselina G. Cooke, Jason R. Dobson, Zhan Deng, Fei Feng, Brant Firestone, Michelle Fodor, Cary Fridrich, Hui Gao, Denise C. Grünenfelder, Huai-Xiang Hao, Jaison Jacob, Samuel B. Ho, Kathy Hsiao, Kang Zhao, Rajesh Karki, Mitsunori Kato, Jay F. Larrow, Laura R. La Bonte, François Lenoir, Gang Liu, Shumei Liu, Dyuti Majumdar, Matthew J. Meyer, Mark Palermo, Lawrence Perez, Minying Pu, Edmund V. Price, Christopher Quinn, Subarna Shakya, Michael D. Shultz, Joanna Slisz, K. Venkatesan, Ping Wang, Markus Warmuth, Sarah Williams, Guizhi Yang, Jing Yuan, Ji-Hu Zhang, Ping Zhu, Timothy M. Ramsey, Nicholas Keen, William R. Sellers, Travis Stams, Pascal D. Fortin - Nature 2016 cited by 946

  3. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

    Authors: Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Silvia Buonamici, Simona Cotesta, Sandra W. Cowan‐Jacob, Stephanie Dodd, Peter Drueckes, Doriano Fabbro, Tobias Gabriel, Jean‐Marc Groell, Robert M. Grotzfeld, Amr Hassan, Chrystèle Henry, Varsha Iyer, Darryl Jones, Franco Lombardo, Alice Loo, Paul W. Manley, Xavier Pellé, Gabriele Rummel, Bahaâ Salem, Markus Warmuth, Andrew A. Wylie, Thomas Zöller, Andreas L. Marzinzik, Pascal Furet - Journal of Medicinal Chemistry 2018 cited by 447

  4. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

    Authors: Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke, Sandra W. Cowan‐Jacob, Alice Loo, Pascal Furet, Andreas L. Marzinzik, Xavier Pellé, Jerry Donovan, Wenjing Zhu, Silvia Buonamici, Amr Hassan, Franco Lombardo, Varsha Iyer, Michael R. Palmer, Giuliano Berellini, Stephanie Dodd, Sanjeev Thohan, Hans Bitter, Susan Branford, David M. Ross, Timothy P. Hughes, Lilli Petruzzelli, K. Gary J. Vanasse, Markus Warmuth, Francesco Hofmann, Nicholas Keen, William R. Sellers - Nature 2017 cited by 614

  5. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

    Authors: Michael Seiler, Akihide Yoshimi, Rachel Darman, Betty Chan, Gregg F. Keaney, Michaël Thomas, Anant A. Agrawal, Benjamin Caleb, Alfredo Csibi, E. Egan Sean, Peter Fekkes, Craig Karr, Virginia M. Klimek, George Lai, Linda Lee, Pavan Kumar, Stanley Chun-Wei Lee, Xiang Liu, Crystal MacKenzie, Carol Meeske, Yoshiharu Mizui, Eric Padron, Eunice Park, Ermira Pazolli, Shouyong Peng, Sudeep Prajapati, Justin Taylor, Teng Teng, John Wang, Markus Warmuth, Huilan Yao, Lihua Yu, Ping Zhu, Omar Abdel‐Wahab, Peter G. Smith, Silvia Buonamici - Nature Medicine 2018 cited by 510

  6. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

    Authors: Rachel Darman, Michael Seiler, Anant A. Agrawal, Kian‐Huat Lim, Shouyong Peng, Daniel Aird, Suzanna Bailey, Erica B. Bhavsar, Betty Chan, Simona Colla, Laura Corson, Jacob Feala, Peter Fekkes, Kana Ichikawa, Gregg F. Keaney, Linda Lee, Pavan Kumar, Kaiko Kunii, Crystal MacKenzie, Mark Matijevic, Yoshiharu Mizui, Khin Than Myint, Eun Sun Park, Xiaoling Puyang, Anand Selvaraj, Michael P. Thomas, Jennifer Tsai, John Y. Wang, Markus Warmuth, Hui Yang, Ping Zhu, Guillermo Garcia‐Manero, Richard R. Furman, Lihua Yu, Peter G. Smith, Silvia Buonamici - Cell Reports 2015 cited by 463

  7. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

    Authors: Jianming Zhang, Francisco Adrián, Wolfgang Jahnke, Sandra W. Cowan‐Jacob, Allen G. Li, Roxana E. Iacob, Taebo Sim, John T. Powers, Christine Dierks, Fangxian Sun, Gui-Rong Guo, Qiang Ding, Okram Barun, Yongmun Choi, Amy Wojciechowski, Xianming Deng, Guoxun Liu, Gabriele Fendrich, André Strauss, Navratna Vajpai, Stephan Grzesiek, Tove Tuntland, Yi Liu, Badry Bursulaya, Mohammad Azam, Paul W. Manley, John R. Engen, George Q. Daley, Markus Warmuth, Nathanael S. Gray - Nature 2010 cited by 606

  8. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

    Authors: Jaya Julie Joshi, Heather Coffey, Erik Corcoran, Jennifer J. Tsai, Chia‐Ling Huang, Kana Ichikawa, Sudeep Prajapati, Ming‐Hong Hao, Suzanna Bailey, Jeremy Wu, Victoria Rimkunas, Craig Karr, Vanitha Subramanian, Pavan Kumar, Crystal MacKenzie, Raelene Hurley, Takashi Satoh, Kun Yu, Eunice Park, Nathalie Rioux, Amy Kim, Weidong G. Lai, Lihua Yu, Ping Zhu, Silvia Buonamici, Nicholas Larsen, Peter Fekkes, John Wang, Markus Warmuth, Dominic J. Reynolds, Peter G. Smith, Anand Selvaraj - Cancer Research 2017 cited by 151

  9. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

    Authors: Lee A. Albacker, Jeremy Wu, Peter Smith, Markus Warmuth, Philip J. Stephens, Ping Zhu, Lihua Yu, Juliann Chmielecki - PLoS ONE 2017 cited by 137

  10. Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition

    Authors: Georg Petzold, Pablo Gaínza, Stefano Annunziato, Ilaria Lamberto, Peter Trenh, Laura A. McAllister, Bradley DeMarco, Laura Schwander, R.D. Bunker, Mary Zlotosch, Rohitha Sriramaratnam, Samuel Gilberto, Gerasimos Langousis, Etienne J. Donckèle, Cynthia Quan, Vaïk Strande, Gian Marco De Donatis, Shanique Alabi, Jessica Alers, Michelle Matysik, Camille Staehly, Aurélie Dubois, Arnaud Osmont, Mackenzie Garskovas, David Lyon, L. Wiedmer, Vladimiras Oleinikovas, Raphael Lieberherr, Nooreen Rubin, Daniel T. Lam, Xavier Lucas, Elisa Liardo, Nina Ilic Widlund, Andreas Ritzén, Ramon Miguel Caceres, Dominico Vigil, Jennifer Tsai, Owen B. Wallace, Marisa Peluso, Amine Sadok, Ralph Tiedt, Alison M. Paterson, Vladislav Zarayskiy, Bernhard Fasching, Débora Bonenfant, Markus Warmuth, John C. Castle, Sharon A. Townson - Science 2025 cited by 71

  11. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer

    Authors: Manav Korpal, Xiaoling Puyang, Zhenhua J. Wu, Roland Seiler, Craig Furman, Htoo Zarni Oo, Michael Seiler, Sean Irwin, Vanitha Subramanian, Jaya Julie Joshi, Chris Kedong Wang, Victoria Rimkunas, Davide Tortora, Hua Yang, Namita Kumar, Galina Kuznetsov, Mark Matijevic, Jesse C. Chow, Pavan Kumar, Jian Zou, Jacob Feala, Laura Corson, Ryan E. Henry, Anand Selvaraj, Allison Davis, Kristjan Bloudoff, James J. Douglas, Bernhard Kiss, Morgan E. Roberts, Ladan Fazli, Peter C. Black, Peter Fekkes, Peter G. Smith, Markus Warmuth, Lihua Yu, Ming‐Hong Hao, Nicholas Larsen, Mads Daugaard, Ping Zhu - Nature Communications 2017 cited by 145

  12. Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

    Authors: Silvia Buonamici, Juliet Williams, Michael Morrissey, Anlai Wang, Ribo Guo, Anthony Vattay, Kathy Hsiao, Jing Yuan, John Green, Beatriz Muñoz, Qunyan Yu, Lance Ostrom, Paul Fordjour, Dustin L. Anderson, John E. Monahan, Joseph F. Kelleher, Stefan Peukert, Shifeng Pan, Xu Wu, Sauveur-Michel Maira, Carlos Garcı́a-Echeverrı́a, Kimberly J. Briggs, D. Neil Watkins, Yung-Mae Yao, Christoph Lengauer, Markus Warmuth, William R. Sellers, Marion Dorsch - Science Translational Medicine 2010 cited by 554

  13. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A–SF3b complex

    Authors: Teng Teng, Jennifer Tsai, Xiaoling Puyang, Michael Seiler, Shouyong Peng, Sudeep Prajapati, Daniel Aird, Silvia Buonamici, Benjamin Caleb, Betty Chan, Laura Corson, Jacob Feala, Peter Fekkes, Baudouin Gerard, Craig Karr, Manav Korpal, Xiang Liu, Jason T. Lowe, Yoshiharu Mizui, James Palacino, Eunice Park, Peter G. Smith, Vanitha Subramanian, Zhenhua J. Wu, Jian Zou, Lihua Yu, Agustin Chicas, Markus Warmuth, Nicholas Larsen, Ping Zhu - Nature Communications 2017 cited by 149

  14. Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

    Authors: Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sung Joon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank F. Sun, Auzon Steffy, AnneMarie Culazzo Pferdekamper, Allen G. Li, Sean B. Joseph, Young Ho Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo W. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin C. Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys - Journal of Medicinal Chemistry 2013 cited by 412

  15. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

    Authors: Anna Galkin, Jonathan S. Melnick, Sung Joon Kim, Tami Hood, Nanxin Li, Lintong Li, Gang Xia, Ruo W. Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Peter Ding, Yi Liu, Fangxian Sun, Peter G. Schultz, Nathanael S. Gray, Markus Warmuth - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 377

  16. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

    Authors: Shifeng Pan, Xu Wu, Jiqing Jiang, Wenqi Gao, Yongqin Wan, Cheng Dai, Dong Han, Jun Liu, Nathan Englund, Yan Wang, Stefan Peukert, Karen Miller‐Moslin, Jing Yuan, Ribo Guo, Melissa Matsumoto, Anthony Vattay, Yun Jiang, Jeffrey Tsao, Fangxian Sun, AnneMarie Culazzo Pferdekamper, Stephanie Dodd, Tove Tuntland, Wieslawa Maniara, Joseph F. Kelleher, Yung‐Mae Yao, Markus Warmuth, Juliet Williams, Marion Dorsch - ACS Medicinal Chemistry Letters 2010 cited by 328

  17. Ba/F3 cells and their use in kinase drug discovery

    Authors: Markus Warmuth, Sung Joon Kim, Xiang-ju Gu, Gang Xia, Francisco Adrián - Current Opinion in Oncology 2006 cited by 242

  18. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer

    Authors: Xiaoling Puyang, Craig Furman, Guo Zhu Zheng, Zhenhua J. Wu, Deepti Banka, Kiran Aithal, Sergei Agoulnik, David M. Bolduc, Silvia Buonamici, Benjamin Caleb, Subhasree Das, Sean Eckley, Peter Fekkes, Ming‐Hong Hao, Andrew Hart, René Houtman, Sean Irwin, Jaya Julie Joshi, Craig Karr, Amy Kim, Namita Kumar, Pavan Kumar, Galina Kuznetsov, Weidong G. Lai, Nicholas Larsen, Crystal MacKenzie, Lesley‐Ann Martin, Diana Melchers, Alyssa Moriarty, Tuong-Vi Nguyen, John D. Norris, Morgan O’Shea, Sunil Pancholi, Sudeep Prajapati, Sujatha Rajagopalan, Dominic J. Reynolds, Victoria Rimkunas, Nathalie Rioux, Ricardo Ribas, Amy Siu, Sasirekha Sivakumar, Vanitha Subramanian, Michaël Thomas, Frédéric H. Vaillancourt, John Wang, Suzanne E. Wardell, Michael J. Wick, Shihua Yao, Lihua Yu, Markus Warmuth, Peter G. Smith, Ping Zhu, Manav Korpal - Cancer Discovery 2018 cited by 112

  19. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

    Authors: Jordi Barretina, Giordano Caponigro, Nicolas Stransky, K. Venkatesan, Adam A. Margolin, Sung Joon Kim, Christopher J. Wilson, Joseph Lehár, Gregory V. Kryukov, Dmitriy Sonkin, Anupama Reddy, Manway Liu, Lauren Murray, Michael F. Berger, John E. Monahan, Paula Morais, Jodi Meltzer, Adam Korejwa, Judit Jané‐Valbuena, Felipa Mapa, Joseph Thibault, Eva Bric-Furlong, Pichai Raman, Aaron Shipway, Ingo H. Engels, Jill Cheng, Guoying Karen Yu, Jianjun Yu, Peter Aspesi, Melanie de Silva, Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway - Nature 2012 cited by 112

  20. Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition

    Authors: Georg Petzold, Pablo Gaínza, Stefano Annunziato, Ilaria Lamberto, Peter Trenh, L. L. McAllister, Bradley DeMarco, Laura Schwander, R.D. Bunker, Mary Zlotosch, Rohitha Sriramaratnam, Samuel Gilberto, Gerasimos Langousis, Etienne J. Donckèle, Chao Quan, Vaïk Strande, Gian Marco De Donatis, Shanique Alabi, Jessica Alers, Michelle Matysik, Camille Staehly, Aurélie Dubois, Arnaud Osmont, Mackenzie Garskovas, David Lyon, L. Wiedmer, Vladimiras Oleinikovas, Raphael Lieberherr, Nooreen Rubin, Daniel T. Lam, Nina Ilic Widlund, Andreas Ritzén, Ramon Miguel Caceres, Dominico Vigil, Jennifer J. Tsai, Owen B. Wallace, Marisa O. Peluso, Amine Sadok, Alison M. Paterson, Vladislav Zarayskiy, Bernhard Fasching, Débora Bonenfant, Markus Warmuth, John Castle, Sharon A. Townson - 2024 cited by 18

  21. NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes

    Authors: Drew Adams, Daisuke Ito, Matthew G. Rees, Brinton Seashore‐Ludlow, Xiaoling Puyang, Alex H. Ramos, Jaime H. Cheah, Paul A. Clemons, Markus Warmuth, Ping Zhu, Alykhan F. Shamji, Stuart L. Schreiber - ACS Chemical Biology 2014 cited by 79

  22. Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation

    Authors: Christine Dierks, Ronak Beigi, Gui-Rong Guo, Katja Zirlik, Mario Stegert, Paul W. Manley, Christopher Trussell, Annette Schmitt‐Graeff, Klemens Landwerlin, Hendrik Veelken, Markus Warmuth - Cancer Cell 2008 cited by 512

  23. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway

    Authors: Zainab Jagani, E. Lorena Mora‐Blanco, Courtney G. Sansam, Elizabeth S. McKenna, Boris G. Wilson, Dongshu Chen, Justin Klekota, Pablo Tamayo, Phuong Nguyen, Michael Tolstorukov, Peter J. Park, Yoon-Jae Cho, Kathy Hsiao, Silvia Buonamici, Scott L. Pomeroy, Jill P. Mesirov, Heinz Ruffner, Tewis Bouwmeester, Sarah J. Luchansky, Joshua Murtie, Joseph F. Kelleher, Markus Warmuth, William R. Sellers, Charles W.M. Roberts, Marion Dorsch - Nature Medicine 2010 cited by 253

  24. Essential role of stromally induced hedgehog signaling in B-cell malignancies

    Authors: Christine Dierks, Jovana Grbic, Katja Zirlik, Ronak Beigi, Nathan Englund, Gui-Rong Guo, Hendrik Veelken, Monika Engelhardt, Roland Mertelsmann, Joseph F. Kelleher, Peter G. Schultz, Markus Warmuth - Nature Medicine 2007 cited by 321